Linzhi Zhang
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
A multi-center retrospective study on the efficacy and safety of regorafenib vs. regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinoma.
Journal: Annals of translational medicine
Published: October 31, 2022
Efficacy and Safety of Tyrosine Kinase Inhibitors Alone or Combination with Programmed Death-1 Inhibitors in Treating of Hepatitis C-Related Hepatocellular Carcinoma.
Journal: Journal of hepatocellular carcinoma
Published: October 12, 2022
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients.
Journal: Hepatology international
Published: October 11, 2022
Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors.
Journal: Hepatology international
Published: September 15, 2022
Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study.
Journal: Drug design, development and therapy
Published: August 23, 2022
TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure.
Journal: Frontiers in pharmacology
Published: August 23, 2022
The advanced development of molecular targeted therapy for hepatocellular carcinoma.
Journal: Cancer biology & medicine
Published: June 14, 2022
Complete Response to PD-1 Inhibitor in Primary Hepatocellular Carcinoma Patients Post-Progression on Bi-Specific Antibody Conjugated CIK Cell Treatment: A Report of Two Cases.
Journal: OncoTargets and therapy
Published: August 10, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026